

Table S1: Clinical testing results and demographic information for study cohort.

Participant	Age (years)	Bleeding Disorder Diagnosis	Secondary diagnosis(es)	VWF Activity (U/mL)	VWF Antigen (U/mL)	Factor VIII Activity (U/mL)	Hemoglobin (g/dL)	Platelet count (K/cu mm)	Platelet Aggregation Results	PFA
1	14	No clinically-identifiable BD; lost to follow up	Vitamin D deficiency	1.12	0.59	1.46	13.5	265	Not done	Normal
2	16	Hyper-mobile EDS	Iron deficiency anemia	1.15	0.82	1.72	11.4	295	Not done	Normal
3	18	BD, NOS	Iron deficiency	0.95	1.05	1.17	13.6	306	Normal	Not done
4	15	No clinically-identifiable BD	Iron deficiency, ovarian cyst	0.82	0.66	1.38	12.6	298	Not done	Normal
5	17	QPD and thrombocytopenia*	Thyroid nodule	1.42	1.27	2.02	14.2	77	Normal	Not done
6	17	QPD	Low VWF, iron deficiency anemia	0.45	0.45	1.26	11.9	513	Impaired response to ADP 1:5, epinephrine 1:10 and 1:100	Epinephrine only prolonged
7	14	Hyper-mobile EDS	Low VWF	0.43	0.38	0.87	13.4	298	Not done	Normal
8	15	No clinically-identifiable BD	Iron deficiency	0.8	0.95	1.2	13.8	302	Normal	Normal
9	15	Type 1 VWD	Iron deficiency anemia	0.19	0.21	0.48	11.5	331	Not done	ADP only pro-longed
10	17	Low VWF	None	0.36	0.45	0.87	13.3	258	Not done	Not done
11	17	No clinically-identifiable BD	None	0.76	0.66	1.32	14.9	301	Normal	Normal
12	13	No clinically-identifiable BD	Iron deficiency anemia	0.84	0.77	1.52	9.6	438	Not done	Normal
13	14	No clinically-identifiable BD	Iron deficiency	0.7	0.58	0.95	12.8	253	Not done	Normal
14	16	QPD	Iron deficiency	1.44	1.14	1.44	12.5	217	Impaired response to ADP 1:5, epinephrine 1:10 and 1:100	ADP and epinephrine prolonged
15	14	No clinically-identifiable BD	Iron deficiency anemia	0.62	0.63	1.29	11.6	376	Not done	Not done

*Platelet-mapping thromboelastography demonstrated a defect in response to ADP. Bleeding symptoms persisted despite improvement of platelet count with steroid administration in this participant.